Evidence map›Paper›PMID 40372590›Full record

SynthesisAnnals of surgical oncology2025

Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) and Liver-Directed Therapy for Synchronous Peritoneal and Liver Metastatic Colorectal Cancer: A Systematic Review with Meta-analysis.

Kadhim Taqi, Simarpreet Icchhpuniani, Cecily Stockley, Golpira Elmi Assadzadeh, Elijah Dixon, Lloyd Mack, Antoine Bouchard-Fortier

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kadhim TaqiDivision of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Kadhim.taqi@ucalgary.ca.
Simarpreet IcchhpunianiDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Cecily StockleyDivision of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Golpira Elmi AssadzadehDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Elijah DixonDivision of Hepatobilliary and Pancreatic Surgery, Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Lloyd MackDivision of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Antoine Bouchard-FortierDivision of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can improve survival in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC). The presence of synchronous liver metastases (LMs) often precludes patients from CRS/HIPEC; however, multiple studies suggest that CRS/HIPEC with liver-directed treatments may be beneficial. This systematic review examines outcomes and selection factors in CRC patients with PC and LM treated with CRS/HIPEC and liver-directed therapy.

methodsA systematic review and meta-analysis was performed using the PubMed, EMBASE, and Web of Science databases from 2009 to 2024. The outcomes included patient selection factors, overall survival (OS) and disease-free survival (DFS).

resultsA total of 482 articles were retrieved, of which 17 retrospective studies met the inclusion criteria, comprising a total of 988 patients. Liver-directed therapy with CRS/HIPEC for PC and LM was associated with 3- and 5-year OS rates of 47% and 37%, respectively, with a median survival range of 15.3-47.6 months. The adjusted 1- and 3-year DFS rates were 34% and 23%, respectively, with a median DFS range of 6.2-29.4 months. Patients with PC and LM were more likely to have received preoperative systemic therapy (86%), undergone minor liver resection (90%), had a limited burden of LM (mean of three lesions, median size of 1.4-3 cm), and limited PC (mean peritoneal cancer index of 13).

conclusionThis study indicates that CRS/HIPEC with liver-directed therapy can yield favorable survival outcomes for well-selected CRC patients with limited PC and LM. Further trials are needed to confirm its efficacy and refine optimal patient selection.

Indexed as

Chemotherapy, Cancer, Regional PerfusionColorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyLiver NeoplasmsPeritoneal NeoplasmsCombined Modality TherapyHumansPrognosisSurvival RateColorectal cancerCRSHIPECLiver resectionPeritoneal carcinomatosisSurvival

Identifiers

PMID40372590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.